Krónikus myeloid leukaemia komplex molekuláris monitorizálása.

Translated title of the contribution: Complex molecular monitoring of chronic myeloid leukemia

J. Vass, L. Kereskai, L. Pajor

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The authors have monitored the treatment of chronic myeloid leukaemia by simultaneous investigation of the residual tumour mass as well as the expression of the bcr-abl chimera. The first parameter was obtained by calculating the bcr-abl rearrangement positive cells as determined by fluorescent in situ hybridisation (FISH). The other value was determined by a quantitative (competitive) reverse transcription polymerase chain reaction (Q-RT-PCR). To avoid any inaccuracy associated with the variable yield of RNA isolation and reverse transcription, respectively, the amount of chimera mRNA was related to that of abl 2-3 transcript as internal control. The threshold for the sensitivity of the Q-RT-PCR procedure was 16 bcr-abl mRNA molecule/microgram RNA. The lowest relative concentration was represented by detecting 1 bcr-abl mRNA molecule out of 12,600 abl 2-3 transcripts. The analysis of peripheral blood samples of 33 untreated patients indicated that the amount of chimera mRNA changes between 80 and 1,000,000 molecules per microgram RNA and this parameter correlated hardly (r = -44) with the tumour load. Data from blood samples of 48 treated patients indicated that this four order of magnitude difference in the expression persists in that patient population which exhibited on average major cytogenetic and also in those without any cytogenetic response. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed.

Original languageHungarian
Pages (from-to)2279-2285
Number of pages7
JournalOrvosi Hetilap
Volume141
Issue number42
Publication statusPublished - Oct 15 2000

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Reverse Transcription
Messenger RNA
Residual Neoplasm
RNA
Cytogenetics
Polymerase Chain Reaction
Tumor Burden
Fluorescence In Situ Hybridization
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Krónikus myeloid leukaemia komplex molekuláris monitorizálása. / Vass, J.; Kereskai, L.; Pajor, L.

In: Orvosi Hetilap, Vol. 141, No. 42, 15.10.2000, p. 2279-2285.

Research output: Contribution to journalArticle

Vass, J, Kereskai, L & Pajor, L 2000, 'Krónikus myeloid leukaemia komplex molekuláris monitorizálása.', Orvosi Hetilap, vol. 141, no. 42, pp. 2279-2285.
Vass, J. ; Kereskai, L. ; Pajor, L. / Krónikus myeloid leukaemia komplex molekuláris monitorizálása. In: Orvosi Hetilap. 2000 ; Vol. 141, No. 42. pp. 2279-2285.
@article{b85d346df24c44e58d0d6b1e89780cc5,
title = "Kr{\'o}nikus myeloid leukaemia komplex molekul{\'a}ris monitoriz{\'a}l{\'a}sa.",
abstract = "The authors have monitored the treatment of chronic myeloid leukaemia by simultaneous investigation of the residual tumour mass as well as the expression of the bcr-abl chimera. The first parameter was obtained by calculating the bcr-abl rearrangement positive cells as determined by fluorescent in situ hybridisation (FISH). The other value was determined by a quantitative (competitive) reverse transcription polymerase chain reaction (Q-RT-PCR). To avoid any inaccuracy associated with the variable yield of RNA isolation and reverse transcription, respectively, the amount of chimera mRNA was related to that of abl 2-3 transcript as internal control. The threshold for the sensitivity of the Q-RT-PCR procedure was 16 bcr-abl mRNA molecule/microgram RNA. The lowest relative concentration was represented by detecting 1 bcr-abl mRNA molecule out of 12,600 abl 2-3 transcripts. The analysis of peripheral blood samples of 33 untreated patients indicated that the amount of chimera mRNA changes between 80 and 1,000,000 molecules per microgram RNA and this parameter correlated hardly (r = -44) with the tumour load. Data from blood samples of 48 treated patients indicated that this four order of magnitude difference in the expression persists in that patient population which exhibited on average major cytogenetic and also in those without any cytogenetic response. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed.",
author = "J. Vass and L. Kereskai and L. Pajor",
year = "2000",
month = "10",
day = "15",
language = "Hungarian",
volume = "141",
pages = "2279--2285",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "42",

}

TY - JOUR

T1 - Krónikus myeloid leukaemia komplex molekuláris monitorizálása.

AU - Vass, J.

AU - Kereskai, L.

AU - Pajor, L.

PY - 2000/10/15

Y1 - 2000/10/15

N2 - The authors have monitored the treatment of chronic myeloid leukaemia by simultaneous investigation of the residual tumour mass as well as the expression of the bcr-abl chimera. The first parameter was obtained by calculating the bcr-abl rearrangement positive cells as determined by fluorescent in situ hybridisation (FISH). The other value was determined by a quantitative (competitive) reverse transcription polymerase chain reaction (Q-RT-PCR). To avoid any inaccuracy associated with the variable yield of RNA isolation and reverse transcription, respectively, the amount of chimera mRNA was related to that of abl 2-3 transcript as internal control. The threshold for the sensitivity of the Q-RT-PCR procedure was 16 bcr-abl mRNA molecule/microgram RNA. The lowest relative concentration was represented by detecting 1 bcr-abl mRNA molecule out of 12,600 abl 2-3 transcripts. The analysis of peripheral blood samples of 33 untreated patients indicated that the amount of chimera mRNA changes between 80 and 1,000,000 molecules per microgram RNA and this parameter correlated hardly (r = -44) with the tumour load. Data from blood samples of 48 treated patients indicated that this four order of magnitude difference in the expression persists in that patient population which exhibited on average major cytogenetic and also in those without any cytogenetic response. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed.

AB - The authors have monitored the treatment of chronic myeloid leukaemia by simultaneous investigation of the residual tumour mass as well as the expression of the bcr-abl chimera. The first parameter was obtained by calculating the bcr-abl rearrangement positive cells as determined by fluorescent in situ hybridisation (FISH). The other value was determined by a quantitative (competitive) reverse transcription polymerase chain reaction (Q-RT-PCR). To avoid any inaccuracy associated with the variable yield of RNA isolation and reverse transcription, respectively, the amount of chimera mRNA was related to that of abl 2-3 transcript as internal control. The threshold for the sensitivity of the Q-RT-PCR procedure was 16 bcr-abl mRNA molecule/microgram RNA. The lowest relative concentration was represented by detecting 1 bcr-abl mRNA molecule out of 12,600 abl 2-3 transcripts. The analysis of peripheral blood samples of 33 untreated patients indicated that the amount of chimera mRNA changes between 80 and 1,000,000 molecules per microgram RNA and this parameter correlated hardly (r = -44) with the tumour load. Data from blood samples of 48 treated patients indicated that this four order of magnitude difference in the expression persists in that patient population which exhibited on average major cytogenetic and also in those without any cytogenetic response. In the individual patients not only correlated changes of residual tumour mass and chimera expression, but mainly independent changes of these two parameters were observed.

UR - http://www.scopus.com/inward/record.url?scp=0034667227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034667227&partnerID=8YFLogxK

M3 - Article

C2 - 11076493

AN - SCOPUS:0034667227

VL - 141

SP - 2279

EP - 2285

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 42

ER -